abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
pharma · CDK Gene Mutation · Solid Tumor, Adult · KZIA
Kazia Therapeutics
KAZIA THERAPEUTICS LTD
Kazia Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
300 Barangaroo Ave, L24, Barangaroo, New South Wales 2000, AU HQ
2016 Founded
15 Employees
Public company Type
KZIA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 300 Barangaroo Ave, L24, Barangaroo, New South Wales 2000, AU
- Founded
- 2016
- Employees
- 15
- Programs
- 13
- Drugs
- 9
- Patents
- 1
Kazia Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kazia Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Kazia Therapeutics in public FDA and regional records.
-
Development asset linked to Kazia Therapeutics in public FDA and regional records.
-
Development asset linked to Kazia Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to Kazia Therapeutics in public FDA and regional records.
-
Development asset linked to Kazia Therapeutics in public FDA and regional records.
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor